Navigation Links
Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
Date:8/3/2011

the brain, these drugs can be delivered directly into the brain without exposing a patient's peripheral organs to the powerful doses needed to kill the cancer cells."  

"We are pleased to be collaborating with Dr. John Zhang and Loma Linda University, and welcome the opportunity to broaden the therapeutic reach of the company into oncology with this cutting-edge program. Our proprietary ability to control the differentiation of neural stem cells into mature, physiologically relevant human neurons and glia, makes it possible for us to pursue this new approach in oncology," said Richard Garr, Neuralstem CEO and President. "Our engineered cells will act as delivery vehicles for anti-cancer therapeutics, a technology which will have wide ramifications for the future use of our cells in multiple indications."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the b
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
2. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
3. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
4. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
5. Neuralstem Completes $5.25 Million Financing
6. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
7. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
(Date:5/21/2013)... Boston, MA (PRWEB) May 21, 2013 ... unified communications platform, Microsoft Lync, for customers in Canada. ... communications software and will allow businesses and organizations ... Last month, SoundConnect released Lync in the United ... US, paired with the product release in Canada, SoundConnect ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... N.Y., April 9 Is the United ... to study in a post-9/11 America? What,are ... international talent for,American biotechnology research and industrial ... in the department of biomedical,engineering at Boston ...
... acquire common stock held by American Red Cross, in ... ProMetic,s stake in PRDT to 77%, - American Red ... of PRDT, MONTREAL and CAMBRIDGE, England, April 9 ... ProMetic,has signed a Letter of Intent ("LOI") to acquire ...
... Inc. (TSX:,ARI), a biotechnology company discovering and developing the next wave ... Where: St. Andrew,s Club & Conference Centre, S7 ... 150 King Street West, 27th Floor, Toronto, Ontario, When: ... Webcast: ARIUS Research Inc.,s Annual and Special Meeting will be webcast ...
Cached Biology Technology:ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 7ARIUS 2008 Annual and Special Meeting of Shareholders 2
(Date:5/21/2013)... keeping in shape is an uphill battle? Try staying ... prolonged weightlessness withers muscle and bone. , That,s the ... address with a new three-year, $1.2 million grant from ... exercise during multiyear exploratory missions. , "You could give ... you can,t get them to stick to it, it ...
(Date:5/21/2013)... CAMBRIDGE, MA -- Over the past few decades, scientists ... including angioplasty balloons and metallic stents. While generally effective, ... of side effects. , A new study from MIT ... combines the benefits of angioplasty balloons and drug-releasing stents, ... a balloon is inflated in the artery for only ...
(Date:5/21/2013)... Australian scientists have charted the path of insulin action ... provides a comprehensive blueprint for understanding what goes wrong ... Sean Humphrey and Professor David James from Sydney,s Garvan ... early online edition of the prestigious journal Cell ... hormone plays a very important role in the body ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3
... of Illinois at Chicago have identified a novel function for ... in acute respiratory distress syndrome, also known as ARDS. ... and treatment of lung inflammation and injury. The research will ... this year and online June 29. ARDS is an ...
... exacerbate drought events throughout the world, resulting in large-scale ... addition, periods of drought vary from year to year ... to adapt to more severe conditions. Many modern ... However, evolution and cultivation in the cold, dry Andean ...
... gardens, we watch them turn gradually from hard, green ... This familiar and seemingly commonplace transformation masks a seething ... complex manner. For generations, agriculturalists and scientists have ... nutrient composition, more or less, one trait at a ...
Cached Biology News:UIC researchers make promising finding in severe lung disease 2Drought tolerance in potatoes 2Drought tolerance in potatoes 3The 21st century tomato 2The 21st century tomato 3
... salt solution. It is routinely used as an ... blood at refrigerator temperatures for approximately 10 weeks.1 ... collected into a container of this product and ... in a refrigerator at 2-8 C for 2 ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
... Chromatograph/Mass Spectrometer, utilizing many of the ... offers high throughput and excellent productivity, ... ratio. Like the GCMS-QP2010 Plus, the ... for optimum separation, 20 temperature ramps, ...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
Biology Products: